drugset / Trial / NCT05016804

Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell IV Infusion for Systemic Sclerosis

NCT05016804

NaSingle-groupOpen-labelTreatment

Summary

This trial will study the safety and efficacy of intravenous infusion of cultured allogeneic adult umbilical cord derived mesenchymal stem cells for the treatment of Systemic Sclerosis

Timeline

Start
2022-07-04
Primary completion
2026-11
Completion
2026-11

Drugs

EvaluationDrugModalityDoseRoute
Subject AlloRx Cell therapy 100 cells Intravenous

Indications